Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Efgartigimod's Real-World impact on CIDP patients

NCT ID NCT07264426

Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over up to 2 years in everyday clinical settings. The goal is to see how well the drug works outside of controlled trials and understand patients' treatment journeys.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
efgartigimod (a biologic drug given as an injection under the skin)
What this could lead to
If successful, this study could show that efgartigimod helps people with CIDP manage their symptoms and improve daily function in real-world conditions.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows people for 2 years, and long-term benefits or risks remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult CIDP participants considered to be initiating efgartigimod treatment per country-specific label for the treatment of CIDP

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years at time of providing informed consent * Diagnosed with CIDP * Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country * Efgartigimod treatment-naïve at time of screening Exclusion Criteria: * Polyradiculoneuropathy due to any other cause(s) * Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic inflammatory demyelinating polyradiculoneuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy polyneuropathy, inflammatory demyelinating, chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic inflammatory demyelinating polyradiculoneuropathy CIDP Cidp (chronic inflammatory demyelinating polyradiculoneuropathy)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    23 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Alexianer St. Josef Potsdam GmbH

    RECRUITING

    Potsdam, 14471, Germany

    Contact Email: •••••@•••••

  • Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

    RECRUITING

    Bochum, 44789, Germany

    Contact Email: •••••@•••••

  • Diakonie-Klinikum Schwäbisch Hall gGmbH

    RECRUITING

    Schwäbisch Hall, 74523, Germany

    Contact Email: •••••@•••••

  • Friedrich-Baur-Institute München

    RECRUITING

    München, 80336, Germany

    Contact Email: •••••@•••••

  • Immanuel Klinik Rüdersdorf

    RECRUITING

    Rüdersdorf, 15562, Germany

    Contact Email: •••••@•••••

  • Jüdisches Krankenhaus Berlin

    RECRUITING

    Berlin, 13347, Germany

    Contact Email: •••••@•••••

  • Medizinische Hochschule Hannover

    RECRUITING

    Hanover, 30625, Germany

    Contact Email: •••••@•••••

  • Mühlenkreiskliniken - Johannes Wesling Klinikum Minden

    RECRUITING

    Minden, 32429, Germany

    Contact Email: •••••@•••••

  • Neurologie Neuer Wall - Dr.Bredow & Partner

    RECRUITING

    Hamburg, 20354, Germany

    Contact Email: •••••@•••••

  • PPD Virtual

    RECRUITING

    Wilmington, North Carolina, 28401, United States

    Contact Email: •••••@•••••

  • UK-RUB - Katholisches Klinikum Bochum - St. Josef Hospital

    RECRUITING

    Bochum, 44791, Germany

    Contact Email: •••••@•••••

  • UKGM - Universitätsklinikum Gießen und Marburg GmbH

    RECRUITING

    Giessen, 35392, Germany

    Contact Email: •••••@•••••

  • Universitatsklinikum des Saarlandes

    RECRUITING

    Homburg, 66424, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Düsseldorf

    RECRUITING

    Düsseldorf, 40225, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Frankfurt

    RECRUITING

    Frankfurt, 60590, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Gießen und Marburg GmbH - Standort Marburg

    RECRUITING

    Marburg, 35043, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Hamburg Eppendorf

    RECRUITING

    Hamburg, 20251, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Köln

    RECRUITING

    Cologne, 50937, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Magdeburg A.ö.R.

    RECRUITING

    Magdeburg, 39120, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Mannheim

    RECRUITING

    Mannheim, 68167, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Tübingen

    RECRUITING

    Tübingen, 72076, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Ulm

    RECRUITING

    Ulm, 89081, Germany

    Contact Email: •••••@•••••

  • Universitätsmedizin Göttingen

    RECRUITING

    Göttingen, 37075, Germany

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.